Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN104 in Combination with Chemotherapy or Venetoclax/Azacitidine for AML
NCT06746519Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BN104 in acute myeloid leukemia (AML) (3 arms). Primary endpoint: Safety and Tolerability of BN104 in combination with Venetoclax/Azacitidine or intensive chemotherapy. Started Dec 2024; status: recruiting.
02
Drugs
BN104
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06746519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746519.